New Delhi

Strides Pharma Science Ltd on Monday reported a 51 per cent jump in its consolidated net profit for the fourth quarter ended March 31, 2026, driven largely by robust growth in its key international markets outside the United States.

The pharmaceutical company posted a net profit of Rs 129.28 crore during the January–March quarter of FY26, compared with Rs 85.62 crore in the corresponding quarter of the previous financial year.

Revenue from operations during the quarter rose to Rs 1,323.47 crore, up from Rs 1,190.39 crore in the same period last year.

According to the company’s investor presentation, revenue from its core markets excluding the US increased sharply to Rs 645.8 crore during the quarter, compared with Rs 480 crore a year earlier. Revenue from the US market, however, remained largely stable at Rs 646.7 crore, slightly lower than Rs 651.5 crore reported in the year-ago period.

Total expenses during the quarter also increased to Rs 1,178.59 crore, compared with Rs 1,071.71 crore in the corresponding quarter last year.

For the full financial year 2025-26, Strides Pharma reported a consolidated net profit of Rs 574.52 crore. In comparison, the company had posted a significantly higher profit of Rs 3,597.51 crore in FY25, largely supported by gains from discontinued operations amounting to Rs 3,188.11 crore.

Annual revenue from operations rose to Rs 4,858.68 crore in FY26, up from Rs 4,565.34 crore in the previous fiscal.

Commenting on the results, Badree Komandur said the company delivered strong growth across profitability, operational efficiency, and business expansion during FY26, primarily driven by performance in markets outside the US.

He noted that the company’s calibrated strategy in non-US markets continues to generate results, with those markets growing faster than the company’s overall business. He added that the US business remained stable during the year, although it was impacted by a weaker flu season in the second half.

Despite geopolitical uncertainties and a challenging global business environment, Komandur said the company remains focused on delivering sustainable and profitable long-term growth.

READ MORE: Shahida Murtaza's academic research forms backbone of governments' policies

Meanwhile, the board of directors has recommended a final dividend of Rs 5 per equity share of face value Rs 10 each for FY26.